The unanimous decision mirrors the FDA conditions for those who qualify for a Pfizer booster.Subscribe for freeDespite small data sample sizes and limited data, the agency noted several times it would need a strong justification to say no to Moderna boosters when it already approved these conditions for Pfizer.
Antibody levels dropped six to eight months after vaccination, however, according to Miller. A half-dose booster at least six months after initial vaccination restored those antibodies in a study of nearly 300 people.Moderna has been in the hot seat this past week over its distribution of vaccine doses globally.
The presented data from Israel indicated boosters for Pfizer reduced the rate of severe disease by 60-80%. The number of severe cases in people under 40, however, was too small to conclude.Until this point, the agency has only voted on boosters for Americans who received the Pfizer vaccine, leaving Moderna and Johnson & Johnson recipients with little guidance as data trickle in.
New data from the National Institutes of Health show people who got the Johnson & Johnson vaccine might benefit from getting a Pfizer or Moderna booster shot. But J&J has asked the FDA to approve a second shot for its own vaccine.